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The similarities between the human and mouse genomes often allow researchers to make accurate predictions
about the roles of their human counterparts. Because of the similar physiology between these two mammals, mice
are used extensively in the laboratory to investigate the mechanisms of human diseases. Furthermore, mice pro-
vide us with the option of testing the toxicity of drugs and the safety of therapeutic approaches prior to human
application. Here, we review the existing mouse models involving the keratin genes (K6a, K6b, K16, and K17) that
cause the human genetic disorder pachyonychia congenita (PC). We also suggest methods to more accurately
model this autosomal dominant skin condition in the mouse in order to better understand the pathophysiological
processes underlying PC and importantly, provide a test-bed for testing emerging therapies in vivo.
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Mice as Reliable In Vivo Models to Mimic
Human Diseases
Although their exact physiology may differ, mice are still
believed to be one of the most reliable models for mimicking
human diseases. Genetically engineered mouse models
mimic most human disease phenotypes faithfully. In some
instances, however, they may reproduce only certain as-
pects of the human disease, may be more severely affected
than the human cases, or may have no clinical phenotype at
all. Nevertheless, in many cases, mouse models of human
diseases have allowed researchers to uncover the progres-
sion and underlying mechanisms of the disease process.
Genetically engineered mice include transgenic mice,
knockout mice, and knock-in mice. Figure 1 illustrates
how these mouse models are generated. Genetically engi-
neered mouse models have provided researchers with val-
uable in vivo tools to study skin cancer, skin development,
and inherited skin diseases.
During the last decade, substantial progress has been
made in determining the genetic basis of several inherited
skin diseases (Lane and McLean, 2004). The success of
these efforts now allows investigators to rationally design
therapeutic strategies for these diseases. In this regard,
advances in vector design and the development of efficient,
safe, and specific delivery systems, have made it possible
to contemplate the use of gene therapy approaches for
correcting inherited skin diseases. Prior to testing gene
therapy approaches in human patients, one would ideally
like to test the safety and efficacy of these approaches in an
animal model that mimics the human disease both genet-
ically and clinically. This review will briefly describe all ex-
isting mouse models that have been generated with genetic
alterations in genes that have been shown to cause
pachyonychia congenita (PC) in humans. Currently, there
are no mouse models that accurately reproduce the clinical
phenotypes observed in PC patients. We will attempt to
explain why previous mouse models have failed to exhibit
PC phenotypes. Finally, we will outline a strategy for gen-
erating what we believe would be an ideal mouse model for
PC. We anticipate that this mouse model will be a valuable
resource to other investigators in their attempts to develop
and test therapeutic approaches for PC.
Current Mouse Models with Genetic
Alterations in Genes Implicated in PC
As described by Leachman et al (in this issue), the clinical
features of PC include various ectodermal abnormalities
characterized most distinctly by the presence of hypertro-
phic nail dystrophy (nail bed hyperkeratosis with nail plate
thickening and deformation) and focal keratoderma. Briefly,
dominant-negative mutations in keratins 6a or 16 (K6a, K16)
cause PC-1, whereas similar mutations in K6b or K17 are
associated with the PC-2 phenotype. Ideally, a PC mouse
model should be able to represent the clinical manifestation
and genetic changes in PC. To date, there are seven mouse
models carrying genetic modifications of PC-related genes.
The characteristics of these mouse models are summarized
in Table I.
K6a mutant mouse models The first mouse model engi-
neered to express a mutant form of K6a was established by
the laboratory of Pierre Coulombe (Takahashi and Cou-
lombe, 1996). The Coulombe laboratory created a trans-
genic mouse with an internal deletion of 52 amino acids
between the head and 1A helix domain of human K6a (for
Abbreviations: EBS, epidermolysis bullosa simplex; EHK,
epidermolytic hyperkeratosis; PC, pachyonychia congenita
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details of the functional domains of keratins, see Smith et al,
in this issue) followed by a c-myc tag, designated as DK6a-
myc. The deleted region includes N171, a mutational ‘‘hot
spot’’ for PC-1 (Lin et al, 1999). Expression of the transgene
was achieved by topical application of the phorbol ester,
TPA. Although the mutant K6a protein produced from the
DK6a-myc transgene acts in a dominant-negative fashion
and interferes with the formation of 10 nm (intermediate)
filaments, it does not resemble any known mutation found in
PC patients, as it is a major deletion (52 amino acids). In
addition, the expression characteristics of the transgene
were not comparable with that of the endogenous MK6a
gene because the latter is artificially modified to be over-
expressed. As a consequence, this mouse model did not
exhibit a naturally occurring PC phenotype. Instead, intra-
epidermal blisters were only observed after TPA-treated
skin was subjected to tape stripping. The lack of a char-
acteristic PC phenotype in this mouse model was most
likely because of the fact that a transgenic approach was
used in its generation, not a knock-in approach.
Our laboratory also generated transgenic mice express-
ing a mutant form of MK6a that was truncated at the be-
ginning of the 2B region of the rod domain (D2B-P) (Wojcik
et al, 1999). Some of these mice exhibited a severe and
lethal skin blistering phenotype. Others, expressing low
levels of the truncated MK6a transgene, survived to adult-
hood without blisters but developed severe alopecia. Sim-
ilar hair loss was also seen in animals that expressed
another mutant K6a transgene in which the E2 domain of
MK6a was replaced by the C-terminus of human K1, which
encodes an epitope tag (DE2-HK1). Mice expressing this
transgene developed hyperkeratotic skin lesions and alo-
pecia beginning around 8–10 wk of age (Wojcik et al, 1999).
Despite the fact that both of these transgenic lines
Figure 1
Generation of transgenic and knock-in/
knockout mouse models. (A) Generation
of transgenic mouse model. Recombinant
DNA carrying genetic information is engi-
neered before it is injected in the male
pronucleus of a fertilized oocyte. The re-
combinant DNA is inserted randomly into
the genome of the oocyte. The oocyte
develops into an early mouse embryo and
the embryo is implanted into the uterus of
a pseudopregnant mouse. The mouse
that develops from the modified oocyte
carries the recombinant transgene in a
random location, therefore, transgene ex-
pression may occur in an uncontrolled
fashion. (B) Generation of knock-in or
knockout mouse model. Defined genetic
modification is constructed in a targeting
vector, which carries a drug resistant se-
lection marker and homologous regions.
The homologous regions define the spe-
cific region of genomic integration. The
targeting vector is electroporated into
mouse embryonic stem (ES) cells. Cor-
rectively targeted ES cells are selected by
antibiotics and expanded. ES cells are in-
jected into an early mouse embryo and
the embryo is implanted into the uterus of
a pseudopregnant mouse. Chimeric mice,
which develop from the mixture of mod-
ified ES cells and cells of the host embryo,
have fur of both colors. These chimeric
mice are mated with normal mice to ob-
tain mice that are derived exclusively from
the modified ES cells. Germline transmit-
ted mice carry the designated genetic
change (modification of a gene for knock-
in or deletion of a gene for knockout). The
change occurs at the genomic locus of
the gene of interest, therefore, its gene
expression (for knock-in) is under the
same control as for the endogenous
wild-type allele.
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expressing different mutant forms of MK6a developed alo-
pecia and hyperkeratosis in some regions of the skin, nei-
ther developed hyperkeratosis of the paws or the oral
cavity, or hypertrophic nails as would be expected for PC-1.
This is most likely because of the fact that MK6a transgenes
used in these experiments were not efficiently expressed in
the oral cavity, foot pads, or nail beds.
MK6a knockout mouse model To further investigate the
function of K6a, our laboratory also deleted this gene from
the mouse genome (Wojcik et al, 2000). Surprisingly, the
K6a-null mice did not exhibit apparent structural defects in
the skin and its appendages. Also, the healing of full thick-
ness skin wounds in these mice was normal compared with
WT littermates. However, a delay in re-epithelialization fol-
lowing tape stripping to remove all layers of the epidermis,
was observed. As the phenotypic consequences of complete
lack of expression of MK6a are surprisingly minimal in the
mouse, these observations are potentially relevant to thera-
peutic strategies that might be contemplated for PC patients.
It may be difficult to develop strategies that will specifically
eliminate expression of the mutant K6a allele. Alternative
strategies designed to eliminate expression of both the wild-
type and mutant K6a alleles are much more feasible. Impor-
tantly, the subtle phenotype of the MK6a knockout mice
suggests that this strategy may have minimal side effects if
attempted in humans, i.e., if it were possible to specifically
ablate or substantially reduce K6a expression using small
interfering RNA (siRNA) or a similar method, without affecting
K6b expression, this might well ameliorate the phenotype of
PC patients carrying K6a mutations.
MK6a/b knockout mouse models To determine the con-
sequences of loss of expression of both the K6a and K6b
genes, the Coulombe laboratory deleted both genes from
the mouse germline. They discovered that K6a/b-null mice
have changes in the oral mucosa resembling those of PC-1
patients (Wong et al, 2000). This mouse model, however,
lacked obvious alterations in nail morphology, a conspicu-
ous feature in PC, as determined by histological analysis of
cross-sections of the nail tissues of 5–10 d old pups (Wong
et al, 2000). This was most likely because of the fact that the
K6a/b-null mice are representative of a recessive disorder;
i.e., the mice do not express a dominant-negative interfering
mutant keratin protein as found in all of the human forms of
PC.
Our laboratory also produced K6a/b-null mice. However,
unlike the K6a/b-null mice, however, generated by Wong
et al which died postnatally, approximately 25% of our K6a/
b-null mice survived to adulthood (Wojcik et al, 2001). Mice
which failed to survive exhibited oral lesions at the back of
the tongue, similar to those observed by Wong et al. Sur-
prisingly, the surviving double knockout mice did not show
any abnormalities of the hair follicles or nails. This prompted
the search for other K6 genes that might be expressed in
the nail bed and hair follicles, and compensated for the loss
of K6a/b. Immunofluorescent staining of surviving K6a/b-
null mice with an antibody raised against the C-terminus of
MK6b showed cross-reactivity in the hair follicle and nail
bed. Therefore, the K6a/b-null mice led to the discovery of a
third isoform of the MK6 gene family, MK6hf (Wojcik et al,
2001).
MK6hf mouse model MK6hf was named because of its
high homology and similar expression patterns to that of
HK6hf. Based on the knowledge gained from previous
studies on K6a-null and K6a/b-null mice, we hypothesized
that the loss of function of the MK6hf by deleting the gene
from the mouse genome may not exhibit phenotypes be-
cause of possible compensation by K6a and/or K6b.
Among the known mutations in the human K6 genes which
have been reported to cause PC, deletion of codon 171 of
K6a, encoding Asparagine (N), is considered to be a mu-
tational ‘‘hot spot.’’ Therefore, in an attempt to generate
a PC phenotype, we introduced this mutation into the
Table I. Current mouse models with genetic alterations in genes implicated in causing PC
Gene
Type of mouse
model Genetic modiﬁcation Phenotype References
K6a Transgenic Deletion of 52 amino acids (residue
125–176) between head and 1A
helix domain
Interepidermal blister Takahashi and Coulombe (1996)
K6a Transgenic Truncation deleting the 2B region Lethal blister or alopecia Wojcik et al (1999)
K6a Transgenic Replacement of E2 by HK1-tag Hyperkeratosis and late-onset
alopecia
Wojcik et al (1999)
K6a Knockout Deletion of K6a locus Delay of reepithelization Wojcik et al (2000)
K6a/b Knockout Deletion of K6a and K6b locus Blistering in oral mucosa Wong et al (2000)
K6a/b Knockout Deletion of K6a and K6b locus Hyperkeratotic plaque
formation on the tongue
Wojcik et al (2001)
K6hf Knock-in Point mutation of codon N158
(corresponding to mutation of N171
in PC patient)
Defects in hair shaft and fragile
nails
Unpublished data
K17 Knockout Deletion of K17 locus Age and strain specific alopecia McGowan et al (2002)
PC, pachyonychia congenita
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corresponding residue of the MK6hf gene by deleting its
codon 158.
Transfection of this dominant mutant complementary
DNA (cDNA) into PtK2 cells showed that the endogenous
keratin filament network was disrupted, suggesting a dom-
inant-negative effect of the mutation (unpublished data).
Therefore, we proceeded to develop a mouse model in
which one wild-type K6hf allele was replaced with the K6hf
D158 allele. These mutant mice displayed a thin coat of fur
compared with WT littermates. The hair phenotype is more
evident on the ventral side of the body. Microscopically,
blebs were observed along the hair shafts of a small per-
centage of the hair. Some hair shafts have more than one
bleb. This focal keratinization defect (blebs) along the hair
shaft may cause hair fragility and explain the sparse coat of
the mutant mice. In addition to the hair phenotype, nails of
the mutant mice also appear to be fragile and are easily lost,
probably because of fragility of keratinocytes in the nail
bed (unpublished data). The nail phenotype is frequently
observed in mutant adult male mice which are prone to
fighting when housed together. To date, this is the only ge-
netically engineered mouse model to exhibit clinical phe-
notypes similar to those observed in PC patients. The
restriction of the phenotypes to the hair and nails is con-
sistent with the expression pattern of the endogenous K6hf
gene. Thus, this mouse model does not actually mimic PC-1
or PC-2. Instead, these mice suggest that PC patients who
do not exhibit classical features of PC-1 or PC-2, i.e., only
their nails and hair follicles show clinical involvement, may
actually have mutations in HK6hf.
MK17 knockout mouse model Several K17 mutations
have been reported in PC-2 and recent data suggest a link
between the late-onset of PC and K17 (see Smith et al, in
this issue). With respect to mouse models that have been
generated with genetic alterations in K17, K17-null mice
exhibit an age and strain specific alopecia (McGowan et al,
2002). But, no obvious abnormalities were observed in the
nails, as observed for PC-2 patients. The lack of the clas-
sical phenotypic features of PC-2 in this mouse model is
most easily explained by the fact that these mice were not
engineered to express a dominant-negative mutant form of
K17 as observed in human patients. The recently identified
K17n, whose expression is highly restricted in the nails of
mice, may also be a contributing factor in the absence of
PC phenotypes (Tong and Coulombe, 2004).
Other Mouse Models of Inherited Skin
Diseases that Are Relevant to PC
The spatial expression of keratin genes is tightly regulated.
These genes are constitutively expressed or induced in
designated layers of the epidermis. Therefore, studies on
other keratin genes that do not necessarily cause PC may
provide meaningful insights into the pathological course of
PC. In addition, advances in embryonic stem (ES) cell tech-
nology have allowed the generation of mouse models that
mimic many human diseases. But, it is not possible to es-
tablish viable mouse models for all inherited diseases. For
example, newborn mice genetically engineered to repro-
duce inherited forms of skin fragility syndromes often die
a few days after birth because of uncontrolled water loss
and/or severe infections. We think that there are two other
mouse models of inherited skin diseases that are relevant to
PC.
To overcome the problem associated with the lethality
caused by skin fragility syndromes in establishing mouse
models, our laboratory has recently utilized an inducible
system that allows the activation of mutations in a restricted
area of the skin. Using this system, we were able to develop
viable, inducible mouse models that mimic epidermolysis
bullosa simplex (EBS) (Cao et al, 2001) and epidermolytic
hyperkeratosis (EHK) (Arin et al, 2001) at both the genetic
and phenotypic levels. These mouse models have provided
new insights into the molecular and cellular basis of EHK
and EBS and have important implications for gene therapy
approaches for these diseases. As PC exhibits clinical fea-
tures of both EHK and EBS, we provide a brief description
of these mouse models and explain how they might be rel-
evant to PC.
The clinical features of PC-1 are in many respects similar
to EHK, because under constitutive conditions, both K10,
whose mutation is responsible for EHK, and K6a are ex-
pressed primarily in the differentiated layers of the affected
epithelia. Therefore, it is beneficial to describe the trans-
genic mouse model that mimics EHK (Arin et al, 2001). This
mouse model differs from the human disease in that ex-
pression of the mutant K10 allele, which contains an Arg
154 Cys mutation equivalent to the Arg 156 Cys mutation
found in  50% of patients with the severe form of EHK
(Arin et al, 2001), can be restricted to a small area of the
skin.
To develop an inducible model for EHK, a recently de-
veloped transgenic mouse model that allows the focal de-
letion of genomic sequences upon topical application of an
inducer was exploited (Berton et al, 2000). This system uti-
lizes tissue-specific expression of the Cre recombinase
fused to a truncated progesterone receptor (PR1) under the
control of a K14 promoter (K14-CrePR1) (Fig 2). The Cre
recombinase activity in this fusion protein is sequestered in
the cytoplasm until the progesterone antagonist, RU486,
induces translocation of the fusion protein into the nucleus
(Kellendonk et al, 1996). Mice carrying the K14-CrePR1
transgene were bred with heterozygous mtK10neo mice.
RU486 was topically applied once daily to the forelimbs and
chest. After 4 d of RU486 treatment, blisters were observed
on the forelimbs and chest of bigenic pups, whereas they
were never observed on the untreated areas or on treated
monogenic or wild-type pups (Fig 3). Although treatment
with RU486 was terminated after blister formation was ob-
served, persistent focal blistering and hyperkeratosis was
observed throughout the lifespan of treated mice. The
hyperkeratosis of the paw of the mouse resembles palmo-
plantar hyperkeratosis observed in PC-1 patients.
The data summarized above suggests that once the
mutant K10 allele is activated in epidermal stem cells, these
mutant stem cells persist for the life of the mouse. Further
support for this hypothesis and for the fact that EBS stem
cells exhibit very different properties from EHK stem cells
was obtained when the same inducible system was used to
develop a mouse model for EBS (Cao et al, 2001). EBS is
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very similar to EHK, except that blisters develop in the basal
keratinocytes of the epidermis because of a dominant mu-
tation in either K5 or K14. In this respect, PC-1 could also
be similar to EBS, if the HK6a gene is induced in keratin-
ocytes in the basal layer in response to injury or blistering.
Unlike EHK lesions, which persist for the life of the mouse,
EBS blisters healed within 2 wk after induction and never
reappeared (Fig 4) (Cao et al, 2001). Thus, activation of the
mutant K14 allele in epidermal stem cells results in their
rapid displacement whereas EHK stem cells fail to exhibit a
growth disadvantage. The phenotypes exhibited by these
inducible models provide an explanation for the existence of
mosaic forms of EHK, but not EBS.
The schematic shown in Fig 5 illustrates what has been
observed in these inducible models. In the inducible EBS
model, focal activation of the mutant K14 allele occurs in
stem cells, resulting in fragility. With time, neighboring stem
cells (where the neomycin-resistance (neo)-cassette is still
in place) migrate into the area and displace the defective
EBS stem cells. In the inducible EHK model, removal of the
neo-cassette from the mutant K10 gene also occurs in stem
cells. The mutant K10 protein, however, is not expressed in
stem cells, but only in the progeny of stem cells after they
have differentiated and moved into the suprabasal layers.
Therefore, there is no adverse selection against epidermal
stem cells with K10 mutations, and these stem cells con-
tinue to give rise to defective differentiated progeny for the
life of the mouse. Our models suggest that gene therapy
approaches will be very different for EHK and EBS. Whereas
repopulation of a phenotypic area by corrected stem cells is
predicted to occur in the case of EBS (Cao et al, 2001),
successful approaches for EHK will have to include a strat-
egy that allows selection of genetically corrected epidermal
stem cells and ablation of defective EHK stem cells. In
Figure 2
Schematic diagram of the K14-CrePR1 induc-
ible excision system. K14 promoter directs
expression of the fusion protein CrePR1 in the
basal keratinocytes, and it remains inactive in the
cytoplasm. Upon induction with RU486, the fu-
sion protein translocates into the nucleus, where
Cre excises the neo-cassette flanked by two
loxP sites. R154C mutation.
Figure 3
Focal induction of blisters in the inducible
epidermolytic hyperkeratosis (EHK) mouse
model. The left panel shows blister formation
on the forelimbs and chest 4 d after treatment.
Unlike epidermolysis bullosa simplex (EBS)-in-
duced blisters, EHK blisters persist after treat-
ment with the activator is stopped. Shown in the
right panel is a mouse at 3 mo following blister
induction. But, persistent blistering has now
been observed for over 1 y.
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humans, PC resembles the persistent hyperkeratosis phe-
notype as found in EHK. Therefore, the EHK mouse model
suggested that selective ablation of defective PC stem cells
may be indispensable to reverse the phenotype.
During the development of these mouse models, we
made an unexpected observation that has additional impli-
cations for the development of therapeutic approaches for
these diseases. As illustrated in Fig 2, the targeting con-
structs used to make the inducible mouse models for EBS
and EHK contain a neo-cassette, flanked by loxP sites, in
the first intron. We discovered that heterozygous mice
which retain the neo-cassette, either mtK10neo or mtK14neo
express these mutant alleles at levels that are  35%–40%
(mtK10) (Arin et al, 2001) or 50% (mtK14) (Cao et al, 2001) of
the wild-type alleles. As mtK10neo and mtK14neo mice ex-
hibited either very subtle or no detectable phenotypes, re-
spectively, therapeutic strategies designed to increase the
ratio of wild-type K10/K14 to mutant K10/K14 to approx-
imately 2–1 might result in sub-clinical disease. Thus, in
contrast to the general assumption that gene therapy ap-
proaches for dominant diseases must either correct the
mutant allele or completely inhibit its expression, our mouse
models predict that amelioration of the EHK and EBS phe-
notypes may be achieved by partial suppression of the
mutant keratin alleles or over-expression of the wild-type
alleles. This may also be true for PC. Therefore, establishing
a PC mouse model is essential to prove the usefulness of
hypotheses drawn from the above relevant mouse models.
The Ideal Mouse Model for PC
In addition to providing insight into the pathophysiological
mechanisms of PC, it is anticipated that the PC mouse
model will provide investigators with an animal model suit-
able for performing preclinical studies to address issues
such as safety and efficacy that will be required to obtain
approval for clinical trials in humans. Therefore, the ideal
mouse model should mimic PC at both the genetic and
phenotypic levels. Furthermore, as certain therapeutic ap-
proaches for treating PC-1 patients may utilize strategies
that are very selective for nucleotide sequences in the hu-
Figure 4
Focal induction of blisters in the inducible epidermolysis bullosa simplex (EBS) mouse model. The left panel shows the induction of a blister 2
d following treatment with the activator on one paw. Ten days following blister induction (middle panel ). Six months after blister formation the paw
appears normal and no additional blisters develop (right panel ).
Figure 5
Upon topical application of an inducer
to the skin, the mutant alleles are ac-
tivated by excision of the neo-cas-
settes. In the epidermolysis bullosa
simplex (EBS) model, the mutant K14 all-
ele is not only activated in epidermal stem
cells, but also expressed in these cells.
Therefore, these cells are fragile and are
replaced by non-phenotypic stem cells
(mtK14neo) migrating in from the surround-
ing non-treated area. Although the neo-
cassette is excised from the mutant K10
allele in stem cells, the gene is not ex-
pressed in stem cells, but only in the dif-
ferentiated progeny of these cells in the
suprabasal layers of the epidermis. Con-
sequently, there is no selective pressure
against stem cells containing the
mtK10loxP allele. These stem cells persist
and give rise to islands of mutant cells
that result in persistent lesions for the life
of the mouse.
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man K6a gene, the PC mouse model should be engineered
to contain a mutant human K6a allele, i.e., a ‘‘humanized’’
mouse PC model.
As discussed above, it is also imperative that a knock-in
strategy be used in the development of the PC mouse
model, as this will ensure that the mutant allele is expressed
at the same level as the wild-type allele and in the appro-
priate tissues. As summarized in Fig 1, the use of traditional
transgenic approaches results in random integration of the
transgene into the mouse genome and increases the like-
lihood that the transgene will not be able to accurately
mimic the expression levels and patterns of endogenous
genes.
An additional consideration in designing the PC mouse
model is the potential deleterious or even lethal effect of
constitutive expression of a mutant K6a allele. As discussed
above, previous studies demonstrated that constitutive
overexpression of a dominant-negative mutant form of
K6a resulted in severe hair loss and skin fragility that ulti-
mately resulted in death. Therefore, we believe that it would
be prudent to utilize the same inducible system described
above for the EBS and EHK mouse models in the gener-
ation of the PC mouse model. This would permit the in-
duced expression of the mutant K6a allele in restricted focal
areas of the skin and ensure that viability of the mouse
model is maintained.
PC mouse model 1 An inducible mouse model for PC-1
that contains sequences identical to human K6a around the
N171K mutation.
As discussed above, this proposed mouse model should
be viable, and mimic PC-1 at both genetic and phenotypic
levels. To accomplish this aim, an inducible mouse model
should be established in which the mutational region of the
MK6a is replaced with the corresponding sequences found
in mutant HK6a. The strategy to accomplish this goal is
outlined in Fig 6. Based on a blast search of homologous
regions between HK6a and MK6a, it would be technically
easiest and scientifically rational to replace a region be-
tween codon 120 and 168 in exon 1 of MK6a with the cor-
responding sequence of HK6a.
As outlined in Fig 6, an 8 kb genomic sequence of MK6a
is cloned into a plasmid that has a PGK-TK cassette. The
partial replacement of the MK6a gene and introduction of
the mutation can be engineered simultaneously. Ideally, pri-
or to insertion of the neo-cassette in intron 1 of MK6a (Fig
6), the ‘‘humanized’’ mutant MK6a constructs can be
transfected into cell lines to confirm that the mutant K6a
protein is expressed and that it does cause collapse of the
endogenous K18 network.
The final step is to introduce the neo-cassette (Fig 6B).
The ideal neo-cassette for inducible gene targeting has
been engineered in this laboratory. It is flanked by loxP
sites. It also contains multiple polyadenylation sequences
(polyA signals). The neo-cassette not only facilitates the
identification of successfully targeted ES cell clones, but it
also prevents transcriptional read-through, i.e., it acts as a
STOP sequence to prevent expression of the mutant allele.
When the neo-cassette is removed by Cre-mediated re-
combination via the loxP sites, normal transcription is re-
sumed. Thus, induction of the mutant allele is achieved
(Fig 7).
After linearization, the targeting vector will be electropo-
rated into ES cells. FIAU and G418 resistant ES cell colonies
Figure 6
The ‘‘humanized’’ MK6a N160K targeting
vector. (A) MK6a genomic locus and the
backbone of the targeting vector. The figure
illustrates that all exons and a large fragment
of the 50 untranslated region (UTR) is cloned in
a TK vector. (B) The linearized targeting vector.
Part of the MK6a sequence in exon 1 was re-
placed by a fragment of mutant () HK6a (yel-
low box) sequence. A neo-cassette is inserted
in intron 1.
Figure7
Strategy to generate inducible transgenic
mice expressing the N160K mutation. (A)
Genomic locus of MK6a. Exons are represent-
ed by black boxes. (B) Predicted structure of the
‘‘humanized’’ mutant MK6a locus. The neo-cas-
sette with multiple polyA signals in intron 1 pre-
vent gene transcription from the mutant allele.
(C) Predicted structure of the recombinant
MK6a locus after Cre-mediated recombination.
Cre-mediated recombination excises the neo-
cassette from intron 1, thereby activating tran-
scription of the mutant MK6a gene.
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will be screened by Southern blot with the designated 50
probe and 30 probe, as well as the neo-cassette probe,
as outlined in Fig 7. Successfully targeted ES cell clones will
be injected into C57BL/6 blastocysts to obtain chimeric
pups.
Once chimeric pups are born, they will be backcrossed
into the C57BL/6 background to confirm germline trans-
mission. When germline transmission is confirmed, het-
erozygous mice will be mated with mice expressing the
inducible Cre recombinase.
Inducible and constitutive PC mouse models Heterozygous
mice will be mated with our K5-CrePR1 mice (Zhou et al,
2002). Double transgenic mice will be treated topically with
RU486 to confirm focal activation of the mutant ‘‘human-
ized’’ K6a allele and induction of PC-1 phenotypes. Al-
though the inducible mouse model gives us the advantage
of producing viable lines, it is also important to observe the
constitutive effects of the dominant-negative mutation in
mice. Therefore, the neo-cassette from successfully target-
ed ES cell clones should be excised by transfecting a Cre-
expression plasmid. Cre-mediated recombination will ex-
cise the neo-cassette located between the two loxP sites.
These ES cell clones will be transferred into blastocysts to
produce a constitutive PC mouse model.
The animal models described above should mimic PC-1
at both genetic and phenotypic levels. The inducible PC-1
mouse model also ensures that the line will be viable, in
case constitutive expression of the mutant K6a causes
death. The ‘‘humanized’’ mutant sequence also provides
researchers with an ideal preclinical model to assess ther-
apeutic strategies that may eventually be used in humans.
PC mouse model 2 An inducible mouse model for PC-1 in
which the entire coding region is replaced with HK6a se-
quence containing the N171K mutation.
It may be possible to selectively inhibit expression of
mutant K6a transcripts through the use of siRNAs or rib-
ozymes that recognize sequences around the site of the
mutation (see Lewin et al, in this issue). As an alternative
approach, however, it may be feasible to completely elim-
inate expression of both wild-type and mutant K6a alleles.
We previously showed that ablation of the MK6a gene from
the mouse germline had only minor phenotypic conse-
quences (Wojcik et al, 2000). To develop a mouse model to
assess this strategy, it is necessary to completely replace
the MK6a sequence with that of HK6a. This model will
provide numerous target sites to ablate expression of K6,
rather than just those sequences around the site of the
mutation. A potential limitation of such a mouse model ex-
pressing the entire human gene, however, is that the human
gene may not function or it may not function in the same
way as it does in humans. For these reasons, it is best to
keep as many of the potential regulatory regions of the
mouse K6a unaltered as possible, such as the 50 or 30 un-
translated region (UTR) in exon 1 and exon 9. Given the
sensitivity and specificity of the above-mentioned gene tar-
geting methods, the coding region of HK6a should provide
an ample number of sites that can be tested for specific
targeting of HK6a.
Strategies used in construction of this targeting vector
are essentially the same as described for PC mouse model
1, except that all exons and introns of mouse K6a will be
replaced with human exons and introns (excluding the 50 or
30UTR in exon 1 and exon 9) (Fig 8). As described for PC
Mouse Model 1, the targeting vector containing the entire
HK6a sequence and N171K mutation will be electroporated
in ES cells. Multiple probes (not shown), however, are nec-
essary to identify correctly targeted ES cell clones. This is
because of the highly homologous sequence between
MK6a and HK6a. Correctly targeted ES cell clones will be
injected to blastocysts to obtain chimeras. Also as de-
scribed in PC Mouse Model 1, chimeras will be back-
crossed to obtain heterozygous mice.
Inducible and constitutive expression of mutant HK6a in
mice Inducible and constitutive mouse models that express
the mutant HK6a gene can be established as described for
PC Mouse Model 1 (Fig 8).
Replacement of the entire MK6a gene locus is straight-
forward, however, screening for targeted ES cells may be
difficult, as exons 1–6 of HK6a and MK6a are highly ho-
mologous. Alignment of these two genes reveals that there
is a 72 bp consecutively identical sequence in exon 6. Un-
desired homologous recombination may happen between
these regions during ES cell targeting. Therefore, as men-
tioned above, additional probes are needed to screen for
successfully targeted ES cell clones. Also, the HK6a introns
Figure8
Strategy to generate inducible transgenic
mice expressing the entire mutant HK6a
gene. (A) Genomic locus of MK6a. (B) Target-
ing vector. MK6a exons and introns are
replaced by corresponding mutant HK6a gen-
omic sequence (blue). Asterisk represents the
N171K mutation of HK6a. A neo-cassette is
inserted in intron 1. Homologous recombina-
tion between the targeting vector and the
MK6a genomic locus in embryonic stem (ES)
cells is symbolized by X. (C) Predicted structure
of the recombinant MK6a locus. The neo-cas-
sette and its multiple polyA signals in intron 1
prevent gene transcription from the recombin-
ant allele. (D) Predicted structure of the recom-
binant MK6a locus after Cre-mediated recom-
bination. Cre-mediated recombination excises
the neo-cassette from intron 1, thereby acti-
vating transcription of the mutant HK6a gene.
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may result in undesired gene splicing and altered regulation
of expression. To circumvent this problem, an alternative
strategy to target the ES cells may be necessary. The al-
ternative strategy is illustrated in Fig 9.
In this strategy, exon 1 (excluding the 50 UTR) and intron
1 of MK6a will be replaced with that of HK6a, including the
N171K mutation. Then, exon 2–9 (including all introns in
between but excluding 30 UTR of exon 9) of MK6a will be
replaced with the corresponding cDNA of HK6a (Fig 9). This
alternative approach will exchange all of the coding se-
quence of MK6a with the mutant human sequence, but the
inclusion of cDNA encoding exons 2–9 will greatly simplify
ES cell targeting.
Using the PC Mouse Model to Test
Therapeutic Strategies
The ultimate role of the PC mouse model is to provide in-
vestigators with a relevant and reliable source of cells and
tissues, as well as whole animals to assess the efficacy of
various therapeutic approaches. For example, keratin-
ocytes can be isolated from PC mouse skin and cultured
in vitro. These cells can be used to rapidly screen for si-
RNAs designed to specifically degrade mutant K6a tran-
scripts. Likewise, primary keratinocytes from the PC mouse
model can be used to assess the efficacy of other inhibitory
molecules as discussed by Lewin et al (in this issue). Once
effective inhibitory molecules are identified using the in vitro
assays, whole animals can be used to assess their effec-
tiveness in vivo. Because of the barrier functions of the skin,
delivery of inhibitory molecules into intact skin may prove to
be a formidable challenge. In both cases, the mouse model
will be invaluable for the in vivo assessment of different
routes of delivery of inhibitory molecules.
Keratinocytes isolated from the PC mouse model could
also be used to screen libraries of small molecules that
might up-regulate other keratins that would effectively sup-
press the mutant K6a phenotype by diluting its concentra-
tion relative to the wild-type protein. Again, once small
molecules are identified in vitro, their effectiveness and
safety can be assessed in vivo in the PC mouse model.
Conclusions
We anticipate that a PC mouse model that accurately re-
capitulates the human PC phenotype will be a very valuable
tool in initial attempts to develop therapeutic approaches
for this genetic disorder. We are aware that there are major
differences between mouse and human skin, however, such
as hair density and skin thickness. Methods of delivering
therapeutic molecules into mouse skin may not prove ef-
fective for human skin. Therefore, an alternative strategy
would be the use of xenografts of skin from PC patients
onto immuno-compromised mice. The availability of PC
skin biopsies for grafting may limit the use of this model.
Therefore, the combined use of the PC mouse model as a
first screen to identify promising candidate molecules and
the xenograft model as a final proof for efficacy may provide
the ideal combination of preclinical models for the assess-
ment of therapeutic approaches for PC.
In conclusion, mouse models form an essential bridge
that allows testing of in vitro and culture-based therapy
systems in the context of an intact organism before pro-
gressing to human trials.
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